No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.

ABSTRACT:

Background

The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD).

Methodology/principal findings

This double-blind, randomized, placebo-controlled trial was conducted between May 2000 and September 2005 in two hospitals in the Netherlands. 51 patients with mild to moderate AD were enrolled into the study. Patients received 100 mg indomethacin or placebo daily for 12 months. Additionally, all patients received omeprazole. The primary outcome measure was the change from baseline after one year of treatment on the cognitive subscale of the AD Assessment Scale (ADAS-cog). Secondary outcome measures included the Mini-Mental Stat

SUBMITTER: de Jong D 

PROVIDER: S-EPMC2194921 | biostudies-literature | 2008 Jan

REPOSITORIES: biostudies-literature